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ABSTRACT
Type 2 diabetes mellitus (T2DM) is a metabolic 
disorder characterized by elevated blood glucose levels 
and is influenced by both genetic and environmental fac-
tors. It is treated with various classes of oral antidiabetic 
drugs, however, response to treatment is highly variable 
with patients failing to achieve adequate glycemic control. 
Treatment response variability has been associated with 
single nucleotide polymorphisms (SNPs) which influence 
the pharma-cokinetics and pharmacodynamics of drug(s). 
The aim of this study was to evaluate the genetic associa-
tion of 17 SNPs and the response to metformin therapy 
in patients diagnosed with diabetes from the indigenous 
Nguni population of South Africa. One hundred and forty 
indigenous African patients diagnosed with T2DM were 
recruited and genotyped using the MassARRAY® system. 
Therapeutic response of patients was ascertained by a 
change in Hb A1c. Two SNPs (rs1801282 and rs6265) were 
monomorphic. All other variants were within the Hardy-
Weinberg equilibrium (HWE). The T allele of the SLC 
variant rs316009 [odds ratio (OR) = 0.25, 95% confidence 
interval (95% CI) = 0.01-0.09, p value = 0.044] and the 
CT genotype of the PCK1 variant rs4810083 (OR = 2.80, 
95% CI = 1.01-7.79, p value = 0.049) were associated with 
an improved response to treatment after adjustment. No 
association was observed with post Bonferroni correction. 
Moreover, this study provides important additional data 
regarding possible associations between genetic variants 
and metformin therapy outcomes. In addition, this is one 
of the first studies providing genetic data from the un-
derstudied indigenous sub-Saharan African populations.
Keywords: Single nucleotide polymorphisms 
(SNPs); SLC variants; South African cohort; Treatment 
response; Type 2 diabetes mellitus (T2DM).
INTRODUCTION
The prevalence of diabetes mellitus (DM) across the 
world is constantly rising. It is estimated that 642 million 
cases of DM will be reported by the year 2040 [1]. In the 
African region alone, it was found that 15.5 million adults 
were living with DM and, of these, 7.0% originate from 
South Africa [2]. Diabetes mellitus is defined as a chronic 
metabolic disease characterized by prolonged hypergly-
cemia [3].
The prolonged hyperglycemia experienced by di-
abetic patients can result in macro- and microvascular 
complications that increases the risk for heart disease, 
stroke, and damage to the nervous system, retina, kidneys 
and other organs [4,5]. Therefore, DM treatment aims 
to maintain a blood glucose level within the physiologi-
cal range [5]. Therapies implemented include dietary and 
lifestyle modification and the administration of oral anti 
diabetic drugs.
The preferred first line treatment in most clinical 
guidelines for the management of type 2 diabetes mellitus 
(T2DM), accounting for ~90.0% of all DM cases, is met-
formin [6,7]. However, 38.0% of T2DM patients respond 
poorly to metformin [8]. In addition to biguanides, several 
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other classes of drugs are being prescribed to treat T2DM; 
these include: sulfonylureas, meglitinides, thiazolidinedi-
ones, α-glucosidase inhibitors, dipeptidyl peptidase-4 in-
hibitors, glucagon-like peptide-1 agonist, sodium glucose 
cotransporter-2 inhibitors, insulin and its analogues [9-11].
Type 2 diabetes mellitus has been linked to variability 
in candidate genes that interfere with the management of 
glycemic control [9]. These candidate genes are involved 
in drug absorption, transportation, distribution, metabolism 
and the signaling cascade of oral anti diabetic drugs [12]. 
Studies have shown that the T2DM patient’s response to 
treatment is characterized by inter-individual variability 
[13,14]. This variability in response have been linked to 
genetic and environmental factors [15,16].
As metformin is the most common drug prescribed for 
the treatment and management of T2DM, numerous studies 
have been conducted to determine the therapeutic effects 
of metformin in the presence of genetic variants. Amongst 
the variants investigated, the SLC variants feature quite 
often. Tzvetkov et al. [17] observed a variation in the renal 
clearance of metformin in Caucasian males with genetic 
polymorphisms in SLC22A1, SLC22A2 and SLC22A3. 
The renal transport of metformin was associated with a 
glucose lowering effect in combination with SLC47A1 and 
SLC22A1 genetic variants in a Dutch cohort [18]. Chen et 
al. [19] observed a very rare SLC22A1 (R206C) variant in 
Asian patients diagnosed with T2DM. Patients with this 
rare variant demonstrated an altered response to metformin 
treatment. These studies and others like it, demonstrate the 
impact that SLC variants and other genetic variants, have 
on the efficacy and toxicity of prescribed drugs.
Pharmacogenomic and pharmacokinetic studies have 
been conducted on the treatment response to T2DM in 
various populations across the world [20-23]. However, 
even though numerous studies have been conducted, lim-
ited data is available for sub-Saharan African populations 
and other African populations, regardless of the human 
genomic diversity found on this continent. Genetic di-
versity presented by indigenous populations across the 
world, in this instance South Africa, should be explored 
for improved diagnostic techniques and treatment plans 
for conditions such as diabetes, cardiovascular disease and 
cancer. The indigenous Nguni population of South Africa 
was selected for investigation in this study. The Nguni 
population is comprised of the Xhosa, Zulu, Ndebele and 
Swati clades [24-26].
Loci identified in previously studied populations ob-
served anti diabetic drug efficacy may or may not affect 
efficacy in South African populations because of ethnic 
genetic differences. Seventeen single nucleotide polymor-
phism (SNP) biomarkers selected for investigation in this 
study, have previously been associated with T2DM in vari-
ous populations across the world [17-23,27-28]. The aim 
of this study was to investigate the genetic association of 
these 17 SNP biomarkers and the response to anti diabetic 
treatment to determine their suitability for individualized 
metformin therapy in patients diagnosed with T2DM in 
the Nguni indigenous population of South Africa.
MATERIALS AND METHODS
Patients and Study Design. All participants were 
briefed about the project and a consent form was com-
pleted and submitted by each participant before the ex-
periment was conducted. Ethics clearance for this study 
was obtained from the Senate Research Committee of the 
University of the Western Cape [Ethics clearance number 
BM/16/5/19].
Study Participants. A total of 140 T2DM outpatients 
belonging to the indigenous Nguni population of South 
Africa [Swati (n = 10), Xhosa (n = 81) and Zulu (n = 49)] 
were recruited from the Cecilia Makhiwane Hospital (East 
London, Eastern Cape) and Piet Retief Hospital (Mkhondo, 
Mpumalanga). Type 2 diabetes mellitus, according to the 
WHO criteria of 1999: plasma glucose level between 7-13 
mmol/L with glycated hemoglobin (Hb) level between 
7.0 and 11.0%. As some patients had other comorbidities 
(i.e. hypertension and dyslipidaemia) in this study, T2DM 
was diagnosed as a plasma glucose level between 6.0-27.0 
mmol/L. Each patient participating in the study had Hb A1c 
levels measured within 6 month (baseline) and 12 month 
(follow-up) periods. Based on Hb A1c levels, patients were 
prescribed an average metformin dose of 1.95 mg per day 
(with a maximum of 2.55 mg). Patients were categorized as 
controlled if they demonstrated a decreased Hb A1c value 
less than 8.0% at 12 months in comparison to the baseline 
prior to the study. Uncontrolled patients demonstrated an 
increased Hb A1c value more than 8.0% at 12 months in 
comparison to the baseline prior to the study. The classifi-
cation used herein for controlled and uncontrolled T2DM 
has been described previously [29,30].
In this pool of study subjects, 53 patients demonstrat-
ed a controlled T2DM (responders to metformin therapy), 
with the remaining 87 patients demonstrated an uncon-
trolled T2DM (non-responders to metformin therapy). 
Patients were included in the study if they were 18 years 
or older and had been on treatment for at least 1 year 
prior to the study. All patients were on metformin mono-
therapy. Patients with other diseases such as type 1 diabetes 
mellitus (T1DM), malignancies, hyperlipidemia, chronic 
kidney and liver diseases, as well as pregnant patients, 
were excluded from the study. Information about age, 
family history, medical history, demographic parameters 
and medication used was obtained via medical reports and 
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interviews. In addition to this, some patients were also on 
antihypertensive drugs, however, while the present study 
does not exclude drug-drug interactions, studies have not 
shown that other drugs co-administered with metformin 
have any influence on the outcome of a genetic association 
with metformin response.
Data Collection and Laboratory Measurements. 
A trained research nurse took clinical measurements of: 
weight, height and blood pressure (BP). Measurements 
were taken with all participants wearing minimal clothing 
and no shoes. Body mass index (BMI) for each patient was 
calculated as weight (kg) divided by height (m2) (Table 1).
Random venous blood was collected to measure se-
rum glycosylated Hb (Hb A1c) levels. Furthermore, lipid 
profile [which includes: total cholesterol (TC), triglyc-
erides (TG), low-density lipoprotein (LDL) and high-
density lipoprotein (HDL)] was obtained (Table 1). All 
blood samples were sent to relevant clinical laboratory 
centers for analysis.
Single Nucleotide Polymorphism(s) Selection and 
Genotyping. The 17 relevant pharmacogenomic variants 
selected for this study were chosen based upon previous 
publications, where association was made between SNPs 
and response to treatment with metformin. In addition to 
this, variants were also cross-referenced and selected based 
upon an evidence level ranging between 2B-4 dictated 
by the pharmacogenomics knowledge base, accessed on 
February 5 February 2019; PharmGKB (http://www.pharm 
gkb.org) [31].
Genomic DNA was isolated from buccal swabs using 
a standard salt lysis method [32]. Samples were stored at 
–20 °C. DNA was quantified using a NanoDrop™2000/ 
2000c UV/VIS Spectrophotometer (Thermo Scientific, 
Waltham, MA, USA). The SNPs were genotyped using 
the MassARRAY®System IPLEX extension reaction 
(Agena Bioscience, San Diego, CA, USA). Genotypes 
of the selected SNP variants were determined for all the 
study participants (Table 2).
Statistical Analyses. Statistical analysis was per-
formed using the Statistical Package for Social Sciences 
(SPSS) version 25 software (www.ibm.com/spss.statistics). 
Clinical laboratory data and anthropometric measurements 
were expressed as mean ± SD. Hardy-Weinberg equilib-
rium (HWE) p values were calculated for all SNPs using 
MedCalc version 2.2.0.0. (MedCalc Software, Ostend, 
Belgium), where p value(s) of <0.05 were considered to 
be significant and implied that the population was not in 
HWE. Association between variant(s) and response to 
diabetic treatment was measured using odds ratios (ORs), 
95% confidence interval (95% CI) and p value(s) derived 
from logistic regression. The threshold for significance in 
association studies was set at p = 0.05.
RESULTS
Table 1 displays the clinical and biochemical de-
mographics of the study population. All SNPs are within 
HWE with two SNPs (rs1801282 and rs6265) being mono-
Table 1. Clinical and biochemical demographics of the study population. 
Parameters Controlled (n = 53) Uncontrolled (n = 87) p Value
Sex (F; M) F: 36; M: 14 F: 57; M: 30 –
Age (years)   60.7 ± 11.0   58.3 ± 11.4   0.470
Weight (kg)   85.8 ± 19.5   85.4 ± 19.1   0.833
Height (cm) 162.1 ± 7.8 163.1 ± 7.7   0.487
Body mass index   31.9 ± 8.4   30.4 ± 10.7   0.304
Hb A1c (%):
   baseline
   12 months
    7.6 ± 2.0
    6.7 ± 1.2
  11.0 ± 2.9
  11.5 ± 2.9
<0.001
<0.001
Random blood sugar (%)     9.4 ± 3.9   14.5 ± 6.6 <0.001
Systolic blood pressure (mmHg) 147.0 ± 24.0 153.5 ± 23.9   0.130
Diastolic blood pressure (mmHg)   83.9 ± 15.5   90.3 ± 13.7   0.018
Total cholesterol (mmol/L)     4.4 ± 1.1     5.0 ± 1.1   0.001
High-density lipoprotein (mmol/L)     1.2 ± 0.4     1.2 ± 0.4   0.672
Low-density lipoprotein (mmol/L)     2.3 ± 0.9     2.8 ± 0.9   0.007
Triglycerides (mmol/L)     2.0 ± 1.2     2.3 ± 1.1   0.215
Creatinine (g/mol) 157.7 ± 383.1   79.3 ± 29.5   0.317
Glomerular filtration rate (mL/min/1.73 m2   41.7 ± 21.5   52.6 ± 25.0   0.313
Values are presented as mean ± SD. Significant p values (<0.05) are bold.
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rs10783050 EEF1A1P11-RPL7P9   1:96571527 intergenic T>C – 0.932
rs1143623 IL1B   2:112838252 intergenic C>G – 0.309
rs13266634 SLC30A8   8:117172544 missense C>A/T Arg325Trp 0.532
rs13376631 FMO1   1:171266603 intron A>G – 0.903
rs1801282 PPARG   3:12351626 missense C>G Pro12Ala monomorphic
rs249429 PRKAA1   5:40782137 intron C>T – 0.299
rs2815752 NEGR1   1:72346757 intergenic G>A – 0.636
rs316009 SLC22A2   6:160254732 intron C>T/G – 0.595
rs316019 SLC22A2   6:160249250 missense C>A Ala270Ser 0.808
rs391300 SRR 17:2312964 intron C>T – 0.739
rs461473 SLC22A1   6:160122530 intron G>A – 0.898
rs4810083 PCK1 20:57545215 intergenic C>T – 0.145
rs578427 –   6:91702432 intergenic T>C – 0.909
rs622342 SLC22A1   6:160151834 intron A>C – 0.218
rs6265 BDNF; BDNF-AS 11:27658369 missense C>T Val66Met monomorphic
rs819 2675 SLC2A2   3:171007094 intron C>T – 0.674
Table 3. Genotype and allele frequencies of 13 single nucleotide polymorphism(s) demonstrating no significant association  
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Table 4. Genotype and allele frequencies of four single nucleotide polymorphism(s) demonstrating no significant association  
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OR: odds ratio; 95% CI: 95% confidence interval.
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OR: odds ratio; 95% CI: 95% confidence interval.
Percent does not account for missing allele(s) at specific loci.
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morphic (Table 2). Hardy-Weinberg equilibrium p values 
ranged between 0.145-0.932 for all of the studied SNPs in 
the population. Genotype and allele distribution of the 17 
SNPS were determined in all the study participants (Table 
3). Among the SNPs selected for this study, four displayed 
significant association between T2DM and/or genotype or 
allele frequencies prior to adjustment (Table 4). The four 
significantly associated SNPs identified are: rs316009, 
rs316019, rs4810083 and rs578427. Prior to adjustment, 
the heterozygous genotype, i.e. CT, and the minor allele 
T of rs316009 demonstrated significant association be-
tween T2DM and treatment response [p = 0.023 (OR: 
0.20; 95% Cl: 0.05-0.81) and p = 0.027 (OR: 0.22; 95% 
Cl: 0.06-0.84) respectively] (Table 4). The minor A allele 
of rs316019 with a p value of 0.026 (OR: 0.35; 95% Cl: 
0.14-0.88) also showed a significant association (Table 4). 
The heterozygous genotype, i.e. CT of rs4810083 with a p 
value of 0.021 (OR: 0.38; 95% Cl: 0.17-0.86) and the ho-
mozygous minor genotype CC of rs578427 with a p value 
of 0.022 (OR: 4.67; 95% Cl: 1.25-1.83) also demonstrated 
a significant association between T2DM and response 
(Table 4). However, after adjustment, only the T allele of 
rs316009 with a p = 0.044 (OR: 0.85; 95% Cl: 0.01-0.93) 
and the CT genotype of rs4810083 with a p = 0.049 (OR: 
2.80; 95% Cl: 1.01-7.79) could still be associated with a 
response to treatment. Lastly, after Bonferroni correction, 
both rs316009 with a p = 0.088 and rs4810083 with a p = 
0.098, showed a lack of association.
DISCUSSION
In this study the genetic association of 17 pharmacog-
enomic biomarkers and response to metformin treatment 
in the indigenous Nguni population of South Africa was 
determined. Previously, the MATE2K variant, rs12943590 
and the variant rs12752688, had been suggested for inclu-
sion in pharmacogenomic profiling of the Nguni popula-
tion [24]. This study will provide additional pharmacog-
enomic biomarker information about possible associa-
tions between genetic variants and response to metformin 
therapy in the Nguni population.
All SNPs, besides rs1801282 and rs6265 (which were 
shown to be monomorphic), were within HWE and showed 
p values ranged between 0.145-0.932 in the study popula-
tion (Table 2). The two monomorphic SNPs (i.e. rs1801282 
and rs6265) are rare variants, however, they were included 
in the study because of the important roles they play in 
the development and progression of the diabetes disease.
The PPARG variant, rs1801282, is important in the 
development of obesity as well as adipose and muscle 
tissue metabolism [33]. This variant has recently been 
investigated in the development of early visual impairment 
in T2DM Chinese Han population [33] and been associ-
ated with obstructive sleep apnea in Chinese Han and 
Indian subjects diagnosed with T2DM [34,35]. Obesity is 
a known comorbid disease of diabetes and sleep apnea has 
also been associated with diabetes, therefore, this variant 
was included for investigation.
The BDNF gene theoretically plays a significant role 
on the well-being and health of individuals, as it has diverse 
roles throughout the body and brain [36]. The BDNF variant, 
rs6265, has been linked to obesity and T2DM in Chinese 
populations [36,37] and BMI in Korean [38] and British 
populations [39]. Because this variant could affect T2DM, 
comorbid diseases related to diabetes and other physical 
indicators of the progression of diabetes, it was selected 
for the study, regardless of its rarity in African populations.
Genotype and allele distribution of the 17 SNPs were 
determined in all the study participants (Tables 3 and 4). 
Among the SNPs analyzed, 13 of the SNPs selected for 
this study showed no statistically significant association 
between treatment response and the SNP variant (Table 
3). The remaining four variants however, i.e. rs316009 
(genotype p value 0.023; allele p value 0.027), rs316019 
(genotype p value 0.026), rs4810083 (genotype p value 
0.021) and rs578427 (genotype p value 0.022), showed 
a significant association between variant and treatment 
response prior to adjustment (Table 4). This study showed 
an increased treatment response to metformin for T2DM 
patients with SNP variants rs316009, rs316019 and 
rs4810083. In contrast, rs578427 demonstrated a decrease 
in response to treatment. However, post adjustment, only 
the T allele of rs316009 (p value 0.044) and the CT geno-
type of rs4810083 (p value 0.049) were associated with 
treatment response. Post Bonferroni correction rs316009 (p 
value 0.088) and rs4810083 (p value 0.098), demonstrated 
a lack of association. However, this can be attributed to 
the small sample size of the study cohort.
The rs316009 variant is located in a transcription fac-
tor binding motif and is in linkage disequilibrium with the 
non synonymous variant rs316019 [21,40-47]. In previous 
studies, the TT genotype of rs316009 showed an increase 
response to metformin in comparison to the CC and CT gen-
otypes [41]. Unfortunately, the homozygous TT genotype 
was not observed in this study population. From the data 
available, the CT genotype demonstrated a better response 
to treatment in comparison to the CC genotype (Table 4). 
The rs316019 is the most common variant of SLC22A2 in 
many populations and has displayed contradictory results, 
linked to both decreased and increased renal clearance of 
metformin in healthy subjects [5,40,42-45].
The interaction of metformin and other drugs in the 
presence of rs316019 was determined in silico by Sajib et al. 
[43]. Based upon the in silico data generated by Sajib et al. 
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[43], all substrates bind to the same pocket of SLC22A2 and 
substrates fit better to the binding site of the C allele [43]. The 
rs316019 results in a protein change that clears metformin 
from circulation much more slowly than the wild-type [43]. 
The AA genotype, especially in females, has been linked to 
hyperlactacidemia within clinical doses of metformin [43]. 
Thus, dose adjustments based on the rs316019 variant may 
be beneficial to maximize treatment response.
Prior to correction, the A allele was significantly as-
sociated with an improved response to treatment. This is in 
contradiction to studies conducted by Song et al. [44] and 
Wang et al. [42], as well as the in silico data generated by 
Sajib et al. [43]. This data is however in agreement with 
studies conducted by Chen et al. [40]. Other studies also 
indicated no association between this variant and response 
to metformin treatment [17,21].
The SNP variant rs4810083 T allele is not associated 
with a response to metformin treatment in T2DM patients 
[46]. The results obtained in this study, however, may 
suggest that the T allele is most likely to be associated 
with a decrease in response to diabetic treatment as more 
patients in the uncontrolled category carry the T allele in 
comparison to the controlled category. This study group 
also shows the CT genotype to be associated with an im-
proved response to treatment (Table 4). To enable further 
clarity with regard to the significance of this SNP variant, 
more data is required from other population groups as 
well as a bigger sample cohort for the current study group.
In the case of the SNP rs578427, the TT genotype 
has been associated with an increased renal clearance and 
secretion clearance of metformin in comparison to the CC 
genotype in a healthy population [47]. As the accumulation 
of metformin in the body can result in the development of 
lactic acidosis, the TT genotype can thus be associated with 
an improved response to treatment. These results are in 
concordance with the data generated for this study popula-
tion as the CC genotype was shown to be significantly as-
sociated with a decreased response to treatment (Table 4).
Contradictory, as well as inconclusive, results may 
have arisen for a number of reasons. The most relevant be-
ing sample size as well as SNP selection and the approach 
used to analyze individual SNPs. Because SNPs do not 
occur in isolation of each other, but rather as combinations 
forming defined haplotypes, the phenotypic effect of indi-
vidual SNPs is not always consistent with functional effects. 
Thus, genotyping single or a few individual SNPs may fail 
to reflect the true functionality of genetic variants [48]. 
Therefore, it should be recommended that future studies 
evaluate haplotypes to establish the functional effects that 
a collection of SNPs may have on response to treatment.
Conclusions. In this study, two SNP variants 
(rs316009 and rs4810083) were significantly associated 
with improved response to diabetic treatment prior to Bon-
ferroni correction. The greatest limitation of this study 
was the sample size and this has inadvertently affected 
the relevance of significantly associated SNP variants. 
Regardless of this, this study provides additional impor-
tant data regarding possible associations between genetic 
variants and metformin therapy outcomes. In, addition, 
this study is one of the first studies providing genetic data 
from the understudied indigenous sub-Saharan African 
populations.
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